Influenza vaccination triggers a well-studied cascade of immune events: B cells ramp up production of antibodies against the viral surface protein hemagglutinin, while T cells help coordinate and refine the response. What remains far less clear is how a person’s body weight shapes that cascade. A new exploratory study from Augsburg, Germany, now offers a detailed, if preliminary, look at the question, tracking antibody titers and immune cell populations in normal-weight and obese adults over nine months after a seasonal flu shot. The findings, published in BMC Immunology, paint a nuanced picture in which antibody responses looked broadly similar across body mass index groups, while certain cellular immune measures hinted at differences that may matter for long-term protection.
The research drew on the MEGA cohort, a prospective observational study conducted at the Institute of Epidemiology in Augsburg between 2018 and 2021. From 238 participants examined at least once, the analysis focused on a subgroup of 25 adults aged 25 to 65 who had received an influenza vaccine from their treating physician during the 2018/19 season. Eighteen participants were normal weight, defined as a body mass index between 20 and 24.99 kilograms per square meter, and seven had obesity, defined as a BMI of 30 or higher. The study group comprised 21 women and 4 men, with a median age of 44.0 years and a median BMI of 22.5 kilograms per square meter in the overall sample.
Each participant attended four visits over nine months: a baseline examination roughly four to six weeks before vaccination, a second visit 28 days after the shot, and two later visits at 180 and 270 days after the baseline assessment. At every visit, researchers collected fasting blood samples and measured influenza-specific antibody titers against the four strains contained in the quadrivalent inactivated vaccine: A/Michigan/45/2015 (H1N1), A/Singapore/INFIMH-16-0019/2016 (H3N2), B/Colorado/06/2017, and B/Phuket/3073/2013. Neutralizing antibodies were quantified with an automated focus-reduction neutralization test, in which serum samples were serially diluted and mixed with virus before being applied to MDCK cell monolayers. The reported titer corresponded to the highest serum dilution that still reduced viral foci by at least 50 percent.
The cellular side of the immune response was assessed by flow cytometry from fresh blood at each visit. T cells were identified as CD4-positive lymphocytes, regulatory T cells as CD4-positive, CD25-positive, CD27-negative lymphocytes, and B cells as CD19-positive lymphocytes. Because the measured populations were not specific to influenza antigens, the authors caution that the observed changes cannot be read as direct evidence of an influenza-specific cellular response. Still, the repeated sampling design allowed the team to follow how these general immune populations shifted over time in each BMI group and to compare the two groups at each time point.
At baseline, before any vaccination, antibody titers showed no significant differences between the BMI groups. After the shot, titers rose in both groups and stayed above pre-vaccination levels throughout the entire nine-month follow-up. In the normal-weight group, titers for all four analyzed antibodies differed significantly at every post-vaccination visit compared with the baseline visit. The obese group told a slightly different story: only the titers against B/Colorado/06/2017 and B/Phuket/3073/2013 differed significantly from baseline at the later visits. Yet when the researchers compared the two groups directly at each time point, they found no significant differences for any of the four antibody titers at any visit.
One strain stood out from this generally similar pattern. Antibody levels against A/Michigan/45/2015 (H1N1) were higher in obese participants and remained elevated throughout follow-up compared with normal-weight participants, although the authors emphasize that no consistent pattern of greater increase or decrease in antibody titers emerged between the groups. This observation runs counter to some earlier work. Studies in diet-induced obese mice reported reduced vaccine efficacy, lower antibody responses, and higher viral titers, while human research by Sheridan and colleagues linked obesity to a steeper decline in influenza antibody titers and reduced CD8-positive T-cell activation. A more recent study by King and colleagues, however, found no significant difference in influenza vaccine effectiveness between obese and normal-weight individuals, a result more in line with the present findings.
The cellular results carried the more intriguing signals. Among obese participants, regulatory T cell proportions showed a decreasing trend over the nine months, though the trend was not statistically significant within that group. In normal-weight participants, these proportions remained relatively stable. By the fourth visit, Treg proportions differed significantly between the two groups, with a p-value of 0.046. Regulatory T cells are involved in the regulation of memory T cell development, and a mouse study has shown that depleting them impairs the formation of memory T cells. Because memory T cells help mount faster and more effective responses upon re-exposure to an antigen, the authors suggest this declining trend may point to possible differences in long-term vaccine-induced cellular immunity in obesity, though they stress the finding is hypothesis-generating rather than conclusive.
Total T-cell counts showed no clear trends and no significant differences between the groups. B-cell proportions, by contrast, displayed no consistent direction over time but did show significant within-group changes: in the normal-weight group, proportions differed significantly between visits 1 and 4, with a p-value of 0.044, and in the obese group between visits 1 and 2, with a p-value of 0.031. Between the groups, B-cell counts were significantly higher in obese participants at visits 1 and 3. B cells occupy a central position in vaccine-induced immunity, since they produce antigen-specific antibodies and later differentiate into memory B cells and plasma cells that sustain long-term protection through continued antibody production. Elevated leptin concentrations, common in obesity, have been associated with alterations in B cell maturation and function, providing one plausible mechanistic thread connecting body weight to these observations.
The authors situate their findings within a broader biological framework. Obesity is characterized by chronic low-grade systemic inflammation, including elevated levels of proinflammatory cytokines such as IL-6 and TNF-alpha. Higher TNF-alpha levels in elderly individuals have been associated with reduced antibody responses after influenza vaccination, and leptin, an adipocyte-derived cytokine, promotes production of proinflammatory cytokines including TNF-alpha. Insulin signaling adds another layer: in a mouse model, insulin-receptor-deficient T cells showed impaired recruitment and survival of CD4-positive T cells, reduced influenza-specific cytokine production, and diminished CD8-positive T-cell responses after infection. Leptin resistance, common in obesity, may also alter T-cell differentiation, particularly toward the pro-inflammatory Th17 phenotype. These mechanisms could theoretically explain reduced vaccine responsiveness in obesity, but the present study did not identify a consistent increase or decrease in the four antibody titers examined, a result the authors attribute either to limited follow-up data or to the possibility that obesity had no measurable effect on antibody persistence during the nine-month window.
The limitations of the study are substantial and the authors are candid about them. With only seven obese participants against eighteen normal-weight ones, the group sizes were imbalanced and statistical power was limited. Potential confounders such as diet, hypertension, and smoking were not fully accounted for, although hypertension was more common among obese participants at baseline. The immune cells quantified were not influenza-antigen specific, meaning concurrent infections, stress, medications, or comorbidities could have influenced the measured populations. Genetic and epigenetic factors shaping immune cell identity could not be controlled either. The authors therefore frame the entire analysis as exploratory and hypothesis-generating, requiring confirmation in larger, adequately powered studies. Within those bounds, the message is measured: BMI may influence cellular immune responses after influenza vaccination, antibody responses appeared broadly similar across BMI groups in this sample, and clarifying the relationship could eventually inform tailored vaccination strategies for people with obesity, a group already known to face elevated risks of severe outcomes from respiratory virus infections.
Subject of Research: How body mass index relates to influenza antibody titers and immune cell counts after influenza vaccination in adults.
Article Title: Association between body mass index and influenza antibody titer and immune cell count after influenza vaccination: an exploratory study
Article References: Böll, S., Schmitz, T., Eggers, M., Linseisen, J., & Meisinger, C. (2026). Association between body mass index and influenza antibody titer and immune cell count after influenza vaccination: an exploratory study. BMC Immunology, 27(1), Article 89. https://doi.org/10.1186/s12865-026-00903-y
Image Credits: AI Generated
DOI: 10.1186/s12865-026-00903-y
Keywords: influenza vaccination, body mass index, obesity, antibody titers, regulatory T cells, B cells, immune response, MEGA cohort, exploratory study, vaccine immunology, T cells, serology
News Source: Kristina Jarvis. (November 7, 2026). Body Weight May Shape Immune Cell Response to Flu Shots, Small Study Suggests. Scienmag.



